Thiago Cabral1, James E DiCarlo, Sally Justus, Jesse D Sengillo, Yu Xu, Stephen H Tsang. 1. aJonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Department of Ophthalmology, Columbia University Medical Center bEdward S Harkness Eye Institute, New York-Presbyterian Hospital, New York, NY, USA cDepartment of Ophthalmology, Federal University of Espírito Santo, Vitoria, Brazil dDepartment of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil eState University of New York Downstate Medical Center, Brooklyn, NY, USA fDepartment of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China gDepartment of Pathology & Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: The present review seeks to summarize and discuss the application of clustered regularly interspaced short palindromic repeats (CRISPR)-associated systems (Cas) for genome editing, also called genome surgery, in the field of ophthalmology. RECENT FINDINGS: Precision medicine is an emerging approach for disease treatment and prevention that takes into account the variability of an individual's genetic sequence. Various groups have used CRISPR-Cas genome editing to make significant progress in mammalian preclinical models of eye disease, the basic science of eye development in zebrafish, the in vivo modification of ocular tissue, and the correction of stem cells with therapeutic applications. In addition, investigators have creatively used the targeted mutagenic potential of CRISPR-Cas systems to target pathogenic alleles in vitro. SUMMARY: Over the past year, CRISPR-Cas genome editing has been used to correct pathogenic mutations in vivo and in transplantable stem cells. Although off-target mutagenesis remains a concern, improvement in CRISPR-Cas technology and careful screening for undesired mutations will likely lead to clinical eye therapeutics employing CRISPR-Cas systems in the near future.
PURPOSE OF REVIEW: The present review seeks to summarize and discuss the application of clustered regularly interspaced short palindromic repeats (CRISPR)-associated systems (Cas) for genome editing, also called genome surgery, in the field of ophthalmology. RECENT FINDINGS: Precision medicine is an emerging approach for disease treatment and prevention that takes into account the variability of an individual's genetic sequence. Various groups have used CRISPR-Cas genome editing to make significant progress in mammalian preclinical models of eye disease, the basic science of eye development in zebrafish, the in vivo modification of ocular tissue, and the correction of stem cells with therapeutic applications. In addition, investigators have creatively used the targeted mutagenic potential of CRISPR-Cas systems to target pathogenic alleles in vitro. SUMMARY: Over the past year, CRISPR-Cas genome editing has been used to correct pathogenic mutations in vivo and in transplantable stem cells. Although off-target mutagenesis remains a concern, improvement in CRISPR-Cas technology and careful screening for undesired mutations will likely lead to clinical eye therapeutics employing CRISPR-Cas systems in the near future.
Authors: F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang Journal: Cell Date: 2013-08-29 Impact factor: 41.582
Authors: Linlin Yin; Lisette A Maddison; Mingyu Li; Nergis Kara; Matthew C LaFave; Gaurav K Varshney; Shawn M Burgess; James G Patton; Wenbiao Chen Journal: Genetics Date: 2015-04-08 Impact factor: 4.562
Authors: Yao Li; Yi-Ting Tsai; Chun-Wei Hsu; Deniz Erol; Jin Yang; Wen-Hsuan Wu; Richard J Davis; Dieter Egli; Stephen H Tsang Journal: Mol Med Date: 2012-12-06 Impact factor: 6.354
Authors: Yao Li; Wen-Hsuan Wu; Chun-Wei Hsu; Huy V Nguyen; Yi-Ting Tsai; Lawrence Chan; Takayuki Nagasaki; Irene H Maumenee; Lawrence A Yannuzzi; Quan V Hoang; Haiqing Hua; Dieter Egli; Stephen H Tsang Journal: Mol Ther Date: 2014-06-04 Impact factor: 11.454
Authors: Aleksandar Vojta; Paula Dobrinić; Vanja Tadić; Luka Bočkor; Petra Korać; Boris Julg; Marija Klasić; Vlatka Zoldoš Journal: Nucleic Acids Res Date: 2016-03-11 Impact factor: 16.971
Authors: D G Courtney; J E Moore; S D Atkinson; E Maurizi; E H A Allen; D M L Pedrioli; W H I McLean; M A Nesbit; C B T Moore Journal: Gene Ther Date: 2015-08-20 Impact factor: 5.250
Authors: Galaxy Y Cho; Yazeed Abdulla; Jesse D Sengillo; Sally Justus; Kellie A Schaefer; Alexander G Bassuk; Stephen H Tsang; Vinit B Mahajan Journal: Curr Ophthalmol Rep Date: 2017-06-15
Authors: Edward H Wood; Peter H Tang; Irina De la Huerta; Edward Korot; Stephanie Muscat; Daniel A Palanker; George A Williams Journal: Retina Date: 2019-05 Impact factor: 4.256
Authors: Maria D Pinazo-Duran; Kian Shoaie-Nia; Vicente Zanon-Moreno; Silva M Sanz-Gonzalez; Javier Benitez Del Castillo; Jose J Garcia-Medina Journal: Curr Neuropharmacol Date: 2018 Impact factor: 7.363